A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas-Reference-Cited by-同舟云学术

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas

Published:2015-07-10 Issue:19 Volume:6 Page:16981-16997
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Beauchamp Roberta L.¹,James Marianne F.¹,DeSouza Patrick A.¹,Wagh Vilas¹,Zhao Wen-Ning¹,Jordan Justin T.²,Stemmer-Rachamimov Anat³,Plotkin Scott R.²,Gusella James F.¹,Haggarty Stephen J.¹⁴,Ramesh Vijaya¹

Affiliation:

1. Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA

2. Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA, USA

3. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

4. Chemical Neurobiology Laboratory, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Boston, MA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions;Oncology and Therapy;2024-05-17

2. Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models;Neuro-Oncology Advances;2024-01-01

3. Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma;Neuro-Oncology;2023-02-20

4. Meningioma and Other Meningeal Tumors;Advances in Experimental Medicine and Biology;2023

5. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2;Neuro-Oncology Advances;2023-01-01